EUVIMEDEUVIMED entdecken
Crossref

In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10 , a Piperazine Derivative From Ursolic Acid

Andres Camilo Moreno Abadia, Denise Diedrich, Laura Cardozo Vieira, Gloria Narjara Santos da Silva iD, Thayse Freitas da Silveira, Francine Dos Santos, Grace Gosmann, Aline Rigon Zimmer iD, Simone Cristina Baggio Gnoatto iD

Tropical Medicine & International Health · 2026-06 · 31 (6) · 660-668

DOI: 10.1111/tmi.70115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tropical Medicine & International Health, online erschienen am 06.03.2026. Verfasst von Andres Camilo Moreno Abadia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Phytochemistry and Organic Synthesis, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre, Bra…. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Plasmodium berghei, Piperazines. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Council for Scientific and Technological Development (CNPq), Coordination of Superior Level Staff Improvement (CAPES), Research Support Foundation of the State of Rio Grande do Sul (FAPERGS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

LAFIS10, N ‐{3‐[4‐(3‐aminopropyl)piperazinyl]propyl}‐3‐ O ‐acetylursolamide, previously demonstrated potent in vitro antimalarial activity against Plasmodium falciparum strains with nanomolar IC 50 values. This study aimed to assess its in vivo antimalarial efficacy and toxicological profile.

Methods

Female BALB/c mice ( n = 6 animals/group) infected with Plasmodium berghei ANKA strain were treated intraperitoneal with LAFIS10 at doses of 15–125 mg/kg for four consecutive days. Chloroquine diphosphate (30 mg/kg) served as the positive control. Parasitemia and survival were monitored for up to 14 and 28 days, respectively. Acute toxicity was evaluated according to OECD guideline 423 at doses of 300 and 2000 mg/kg. In vitro coagulation and hemolysis assays were conducted using human peripheral blood.

Results

LAFIS10 significantly reduced parasitemia in a dose‐dependent manner, with reductions of 52.46% and 59.59% at 60 and 125 mg/kg, respectively ( p < 0.05). The ED 50 was 19.68 mg/kg, and the maximal effect (Emax) was 52.18%. Mice treated with LAFIS10 survived up to 7 days longer than untreated controls. In vitro coagulation assays showed no significant changes in prothrombin time, while a slight decrease in activated partial thromboplastin time was observed at 100 μM. LAFIS10 displayed dose‐dependent hemolytic activity, and the in vivo LD 50 estimated between 125 and 300 mg/kg, classifying it as toxic (GHS class 3).

Conclusions

LAFIS10 exhibited promising in vivo antimalarial activity but showed hemolytic‐related toxicity at higher doses. Further studies are warranted to optimise its structure or formulation to achieve improved efficacy and safety as a potential antimalarial candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsMalariaPlasmodium bergheiPiperazinesTriterpenesAnimalsFemaleMice, Inbred BALB CMiceParasitemiaHemolysisDose-Response Relationship, DrugHumansBlood Coagulation

Stichwörter der Autor:innen

Plasmodium bergheihemolysismalariapreclinical assaystoxicitytriterpene derivative

Substanzen

AntimalarialsPiperazinesTriterpenes

Autor:innen und Institutionen

  • Laboratory of Phytochemistry and Organic Synthesis, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • School of Pharmacy, Federal University of Bahia, Salvador, Brazil.

ORCID-Profile: Gloria Narjara Santos da Silva, Aline Rigon Zimmer, Simone Cristina Baggio Gnoatto

Förderung

  • National Council for Scientific and Technological Development (CNPq)
  • Coordination of Superior Level Staff Improvement (CAPES)
  • Research Support Foundation of the State of Rio Grande do Sul (FAPERGS)
  • National Institutes of Science and Technology (INCTs)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul

Zitieren

APA

Abadia, A. C. M., Diedrich, D., Vieira, L. C., da Silva, G. N. S., da Silveira, T. F., Dos Santos, F., Gosmann, G., Zimmer, A. R., & Gnoatto, S. C. B. (2026). In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10 , a Piperazine Derivative From Ursolic Acid. Tropical Medicine & International Health, 31(6), 660-668. https://doi.org/10.1111/tmi.70115

Vancouver

Abadia ACM, Diedrich D, Vieira LC, da Silva GNS, da Silveira TF, Dos Santos F, et al. In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10 , a Piperazine Derivative From Ursolic Acid. Tropical Medicine & International Health. 2026;31(6):660-668. doi:10.1111/tmi.70115

BibTeX
@article{Abadia2026,
  author = {Abadia, Andres Camilo Moreno and Diedrich, Denise and Vieira, Laura Cardozo and da Silva, Gloria Narjara Santos and da Silveira, Thayse Freitas and Dos Santos, Francine and Gosmann, Grace and Zimmer, Aline Rigon and Gnoatto, Simone Cristina Baggio},
  title = {In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10 , a Piperazine Derivative From Ursolic Acid},
  journal = {Tropical Medicine & International Health},
  year = {2026},
  volume = {31},
  number = {6},
  pages = {660--668},
  doi = {10.1111/tmi.70115}
}
Kostenlos starten →